Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02132949 |
| Title | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies |
Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | FRA | ESP | DEU | CAN |